Announcements
- Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process
- Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023
- Mithra secures court protection measures to advance monetization process
- Mithra reports full year 2023 financial results
- Mithra announces changes to its executive management
- Mithra initiates monetization process, receives bridge loan from existing lenders
- DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase
- Mithra sells shares in Mayne Pharma
- Mithra updates on cash position
- Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
More ▼
Key statistics
On Wednesday, Mithra Pharmaceuticals SA (0R91:LSE) closed at 0.219, 7.36% above its 52-week low of 0.204, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.22 |
---|---|
High | -- |
Low | -- |
Bid | 0.205 |
Offer | 0.235 |
Previous close | 0.219 |
Average volume | 0.25 |
---|---|
Shares outstanding | 66.91m |
Free float | 54.24m |
P/E (TTM) | -- |
Market cap | 14.45m EUR |
EPS (TTM) | -2.51 EUR |
Data delayed at least 20 minutes, as of Apr 24 2024 17:11 BST.
More ▼